GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Life Sciences

More

  • Gene therapy for deafness moves a few steps closer Wednesday, 8 Jul 2015 | 2:00 PM ET

    *Novartis tests gene therapy in adults with damaged hearing. Separately, a clinical trial backed by Novartis is under way to help a different group of people who have lost their hearing through damage or disease. "We are somewhat late in the auditory field but I think we are getting there now," said Tobias Moser of the University Medical Center Gottingen, Germany, who...

  • TEL AVIV, July 8- As Israel's biggest company Teva strives to get even bigger by swallowing up rival Mylan for more than $40 billion, further down the food chain a raft of upstart life science firms are struggling to climb onto the global ladder. Israel has a burgeoning life science industry comprising around 1,380 mostly very small companies.

  • Sheep Meadow in Central Park is a mixture of four types of turfgrass.

    The U.S. is becoming a much greener place, but turf maintenance comes with a host of environmental considerations.

  • SEOUL, June 29- Samsung Bioepis Co Ltd, a biopharma development unit of Samsung Group, is considering listing on the NASDAQ to raise about 1.5 trillion won to fund biopharma product development, a Bioepis spokeswoman said on Monday. Samsung Group will soon send proposals to investment banks before choosing advisors for the IPO, potentially during the first half...

  • Turf wars: How this $40B industry helps and hurts Saturday, 27 Jun 2015 | 9:00 AM ET
    Sheep Meadow in Central Park is a mixture of four types of turfgrass.

    There are acres of green turf around the country, but lawn maintenance has stirred a debate about its environmental impact.

  • June 26- Drug developer Celladon Corp said on Friday it may liquidate itself if it were unable to find a buyer, and was suspending development of its gene therapy for heart failure. Celladon said if it were to liquidate during the third quarter ending September, the net cash available for distribution to shareholders would be about $25 million- $30 million.

  • Celladon to suspend development of gene-therapy drug Friday, 26 Jun 2015 | 6:44 AM ET

    June 26- Celladon Corp said it would suspend further development of its gene-therapy drug for heart failure, months after the treatment failed a mid-stage trial. Celladon also announced a second reduction in its workforce on Friday. Celladon earlier this month named Wedbush PacGrow Healthcare as its exclusive financial adviser and started a process to seek...

  • June 22- Cancer drug developers Kite Pharma Inc and Bluebird Bio Inc said they would partner to develop and market a new class of T-cell therapies for HPV-associated cancers. The National Cancer Institute has indicated that cell therapies could eventually become the standard of care in the multi-billion market to treat cancer. Juno Therapeutics Inc, another...

  • *Guinea trial last chance to show vaccine efficacy. LONDON, June 17- Drugmakers' plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa. The haemorrhagic Ebola virus has killed more than 11,000 people in Guinea, Sierra Leone and Liberia in an...

  • *Company to meet FDA to discuss regulatory path. June 15- RedHill Biopharma Ltd said its experimental drug met the main goal of eradicating a bacterial infection in a late-stage study, sending its shares up as much as 35 percent to a record high. Ascendiant Capital Market's Edward Woo said the drug is one of RedHill's biggest opportunities and could rake in peak...

  • June 15- RedHill Biopharma Ltd said its experimental antibiotic drug met the main goal in a late-stage study, sending the Israeli drugmaker's U.S.-listed shares up 19.6 pct in premarket trading.

  • LONDON, June 13- A pioneering gene therapy for sickle cell disease is working well so far for a 13- year-old French boy with the hereditary blood disorder, researchers said on Saturday, in a boost for the technology to fix faulty genes. He is the first patient with severe sickle cell disease to be treated with Bluebird Bio's LentiGlobin BB305 product, which the U.S....

  • SHANGHAI, June 12- The World Health Organization has approved a Chinese influenza vaccine as being safe and effective, only the second Chinese vaccine to receive such status reflecting the growing clout of the country's drug makers. The WHO said in a statement on Friday that it had "prequalified" a vaccine made by Hualan Biological Bacterin Corp, a subsidiary of...

  • The USDA has been developing a vaccine against bird flu and was weighing whether to release it to drug makers for widespread production. Turkey producers in Minnesota, where nearly 9 million birds have been affected by the disease since the beginning of the year, had asked the USDA to approve use of a vaccine to help prevent further infections.

  • Could virus make the leap from birds to people? Saturday, 30 May 2015 | 12:02 PM ET
    Lacey Kurth, a research associate, works with avian influenza test samples during testing in the real-time analytical diagnostics lab at the Iowa State University College of Veterinary Medicine in Ames, Iowa.

    There have only been four flu pandemics since the start of the 20th century, yet concerns are widening about the potential for a new outbreak.

  • New class of drugs shows promise for cancer fight Friday, 29 May 2015 | 2:18 PM ET

    A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • May 21- Biotech firm Bluebird Bio Inc said its experimental gene therapy continued to exhibit a positive effect in an ongoing early-stage study of patients with rare types of blood disorders. The product, LentiGlobin, is being tested in patients with beta-thalassemia major and those with severe sickle cell disease, two hereditary conditions.

  • May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...